Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Retained Earnings (2016 - 2025)

Moleculin Biotech's Retained Earnings history spans 10 years, with the latest figure at -$206.0 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$206.0 million for Q4 2025, down 19.46% from a year ago — trailing twelve months through Dec 2025 was -$206.0 million (down 19.46% YoY), and the annual figure for FY2025 was -$206.0 million, down 19.46%.
  • Retained Earnings for Q4 2025 was -$206.0 million at Moleculin Biotech, up from -$221.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$61.4 million in Q1 2021 to a low of -$221.6 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$118.5 million (2023), against an average of -$125.7 million.
  • The sharpest move saw Retained Earnings plummeted 50.51% in 2021, then dropped 19.46% in 2025.
  • Year by year, Retained Earnings stood at -$72.8 million in 2021, then plummeted by 39.86% to -$101.8 million in 2022, then fell by 29.23% to -$131.6 million in 2023, then plummeted by 31.03% to -$172.4 million in 2024, then dropped by 19.46% to -$206.0 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$206.0 million, -$221.6 million, and -$196.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.